Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exenatide-XTEN
- Development stage
- Unknown
- Lead developer
- Diartis Pharmaceuticals
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Exenatide-XTEN is a long-acting recombinant fusion protein designed for the treatment of type 2 diabetes mellitus. It consists of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide fused to an XTEN polymer. XTEN is a non-repetitive, hydrophilic, and biodegradable polypeptide technology developed to extend the half-life of therapeutic peptides by increasing their hydrodynamic radius, thereby reducing renal clearance. As a GLP-1 receptor agonist, exenatide-XTEN mimics the action of endogenous GLP-1, stimulating glucose-dependent insulin secretion, inhibiting glucagon release, and slowing gastric emptying. The fusion protein was engineered to allow for significantly less frequent dosing (e.g., once-monthly) compared to standard exenatide formulations. Development was primarily conducted by Amunix in collaboration with Versartis.
- Other names
- Exenatide-XTENexenatide-XTEN fusion protein
02
Targets
Beyond the preview
Go deeper on exenatide-XTEN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exenatide-XTEN.